Recently, findings from phase 3 trial for first in class novel drug, imeglimin, were presented were presented at EASD meeting in Spain. This drug works to improve mitochondrial function which improves insulin sensitivity and secretion, and decreasing hepatic/liver glucose production (now that it is a great triple action). Results from phase 3 trial in Japan are very positive. Imeglimin is the first in new novel “glimin” class of glucose lowering agents. Now, it is important to keep in mind the medication was studied in Japanese population so it remains to be seen its benefit in other populations. Sound interesting? Please click below to learn more.
Please share your thoughts and subscribe to receive my blogs.
#imeglimin #novel #drug #diabetes
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.